{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,4]],"date-time":"2026-04-04T06:42:59Z","timestamp":1775284979559,"version":"3.50.1"},"reference-count":23,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2015,9,1]],"date-time":"2015-09-01T00:00:00Z","timestamp":1441065600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2015,9,1]],"date-time":"2015-09-01T00:00:00Z","timestamp":1441065600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2016,8,26]],"date-time":"2016-08-26T00:00:00Z","timestamp":1472169600000},"content-version":"am","delay-in-days":360,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/501100007729","name":"Ministerie van Buitenlandse Zaken","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100007729","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000278","name":"Department for International Development, UK Government","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000278","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000780","name":"European Commission","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000780","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000865","name":"Bill and Melinda Gates Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000865","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100008196","name":"M\u00e9decins Sans Fronti\u00e8res","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008196","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002347","name":"Bundesministerium f\u00fcr Bildung und Forschung","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100002347","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Medicinal Chemistry"],"published-print":{"date-parts":[[2015,9]]},"DOI":"10.1016\/j.ejmech.2015.08.013","type":"journal-article","created":{"date-parts":[[2015,8,11]],"date-time":"2015-08-11T04:27:06Z","timestamp":1439267226000},"page":"582-593","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":39,"special_numbering":"C","title":["Aminothiazoles: Hit to lead development to identify antileishmanial agents"],"prefix":"10.1016","volume":"102","author":[{"given":"Debnath","family":"Bhuniya","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rao","family":"Mukkavilli","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2078-7125","authenticated-orcid":false,"given":"Rahul","family":"Shivahare","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6862-4723","authenticated-orcid":false,"given":"Delphine","family":"Launay","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ravindra T.","family":"Dere","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anil","family":"Deshpande","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Aditya","family":"Verma","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Preeti","family":"Vishwakarma","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Manjunath","family":"Moger","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8984-9048","authenticated-orcid":false,"given":"Ashok","family":"Pradhan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hari","family":"Pati","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vadiraj S.","family":"Gopinath","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Suman","family":"Gupta","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sunil K.","family":"Puri","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Denis","family":"Martin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.ejmech.2015.08.013_bib1","doi-asserted-by":"crossref","first-page":"e277","DOI":"10.1371\/journal.pmed.0030102","article-title":"Incorporating a rapid impact package for neglected tropical diseases with programs for HIV\/AIDS, tuberculosis and malaria","volume":"3","author":"Hotez","year":"2006","journal-title":"PLoS Med."},{"key":"10.1016\/j.ejmech.2015.08.013_bib2","first-page":"353","article-title":"Childhood visceral leishmaniasis","volume":"123","author":"Bhattacharya","year":"2006","journal-title":"Indian J. Med. Res."},{"key":"10.1016\/j.ejmech.2015.08.013_bib3","doi-asserted-by":"crossref","first-page":"e371","DOI":"10.1016\/S2214-109X(13)70078-0","article-title":"The drug and vaccine landscape for neglected diseases (2000\u201311): a systemic assessment","volume":"1","author":"Pedrique","year":"2013","journal-title":"Lancet Glob. Health"},{"key":"10.1016\/j.ejmech.2015.08.013_bib4","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1016\/j.cimid.2004.03.004","article-title":"Leishmaniasis: current situation and new perspectives","volume":"27","author":"Desjeux","year":"2004","journal-title":"Comp. Immunol. Microbiol. Infect. Dis."},{"key":"10.1016\/j.ejmech.2015.08.013_bib5","unstructured":"Leishmaniasis. http:\/\/www.who.int\/mediacentre\/factsheets\/fs375\/en\/."},{"key":"10.1016\/j.ejmech.2015.08.013_bib6","doi-asserted-by":"crossref","first-page":"873","DOI":"10.1038\/nrmicro1748","article-title":"Visceral leishmaniasis: what are the needs for diagnosis, treatment and control?","volume":"5","author":"Chappuis","year":"2007","journal-title":"Nat. Rev. Microbiol."},{"key":"10.1016\/j.ejmech.2015.08.013_bib7","first-page":"389","article-title":"Drug unresponsiveness & combination therapy for kala-azar","volume":"123","author":"Jha","year":"2006","journal-title":"Indian J. Med. Res."},{"key":"10.1016\/j.ejmech.2015.08.013_bib8","doi-asserted-by":"crossref","first-page":"1739","DOI":"10.1056\/NEJMoa021556","article-title":"Oral miltefosine for Indian visceral leishmaniasis","volume":"347","author":"Sundar","year":"2002","journal-title":"N.\u00a0Engl. J. Med."},{"key":"10.1016\/j.ejmech.2015.08.013_bib9","doi-asserted-by":"crossref","first-page":"2571","DOI":"10.1056\/NEJMoa066536","article-title":"Injectable paromomycin for visceral leishmaniasis in India","volume":"356","author":"Sundar","year":"2007","journal-title":"N.\u00a0Engl. J. Med."},{"key":"10.1016\/j.ejmech.2015.08.013_bib10","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1016\/j.ijpddr.2012.01.003","article-title":"Visceral leishmaniasis treatment: what do we have, what do we need and how to deliver it?","volume":"2","author":"Freitas-Junior","year":"2012","journal-title":"Int. J. Parasitol. Drugs. Drug. Resist"},{"key":"10.1016\/j.ejmech.2015.08.013_bib11","first-page":"399","article-title":"Current scenario of drug development for leishmaniasis","volume":"123","author":"Croft","year":"2006","journal-title":"Indian J. Med. Res."},{"key":"10.1016\/j.ejmech.2015.08.013_bib12","first-page":"175","article-title":"Drug discovery and development for neglected diseases: the DNDi model","volume":"5","author":"Chatelain","year":"2011","journal-title":"Drug Des. Devel. Ther."},{"key":"10.1016\/j.ejmech.2015.08.013_bib13","doi-asserted-by":"crossref","first-page":"2265","DOI":"10.4155\/fmc.12.176","article-title":"Antimalarial aminothiazoles and aminopyridines from phenotypic whole-cell screening of a SoftFocus((R)) library","volume":"4","author":"Paquet","year":"2012","journal-title":"Future Med. Chem."},{"key":"10.1016\/j.ejmech.2015.08.013_bib14","doi-asserted-by":"crossref","first-page":"1010","DOI":"10.1021\/jm101250y","article-title":"2-Aminothiazoles as therapeutic leads for prion diseases","volume":"54","author":"Gallardo-Godoy","year":"2011","journal-title":"J.\u00a0Med. Chem."},{"key":"10.1016\/j.ejmech.2015.08.013_bib15","doi-asserted-by":"crossref","first-page":"9031","DOI":"10.1021\/jm401557w","article-title":"Aminothiazole-featured pirinixic acid derivatives as dual 5-lipoxygenase and microsomal prostaglandin E2 synthase-1 inhibitors with improved potency and efficiency in\u00a0vivo","volume":"56","author":"Hanke","year":"2013","journal-title":"J.\u00a0Med. Chem."},{"key":"10.1016\/j.ejmech.2015.08.013_bib16","doi-asserted-by":"crossref","first-page":"6385","DOI":"10.1016\/j.bmc.2013.08.048","article-title":"Structure-activity relationships of 2-aminothiazoles effective against Mycobacterium tuberculosis","volume":"21","author":"Meissner","year":"2013","journal-title":"Bioorg. Med. Chem."},{"key":"10.1016\/j.ejmech.2015.08.013_bib17","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/S0169-409X(00)00129-0","article-title":"Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings","volume":"46","author":"Lipinski","year":"2001","journal-title":"Adv. Drug Deliv. Rev."},{"key":"10.1016\/j.ejmech.2015.08.013_bib18","doi-asserted-by":"crossref","first-page":"2615","DOI":"10.1021\/jm020017n","article-title":"Molecular properties that influence the oral bioavailability of drug candidates","volume":"45","author":"Veber","year":"2002","journal-title":"J.\u00a0Med. Chem."},{"key":"10.1016\/j.ejmech.2015.08.013_bib19","doi-asserted-by":"crossref","first-page":"3776","DOI":"10.1128\/AAC.49.9.3776-3783.2005","article-title":"Use of Leishmania donovani field isolates expressing the luciferase reporter gene in in\u00a0vitro drug screening","volume":"49","author":"Ashutosh","year":"2005","journal-title":"Antimicrob. Agents. Chemother."},{"key":"10.1016\/j.ejmech.2015.08.013_bib20","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1016\/j.ejmech.2013.08.028","article-title":"Design, synthesis and biological evaluation of 2-substituted quinolines as potential antileishmanial agents","volume":"69","author":"Gopinath","year":"2013","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.ejmech.2015.08.013_bib21","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1016\/0022-1759(83)90303-4","article-title":"Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays","volume":"65","author":"Mosmann","year":"1983","journal-title":"J.\u00a0Immunol. Methods"},{"key":"10.1016\/j.ejmech.2015.08.013_bib22","doi-asserted-by":"crossref","first-page":"3342","DOI":"10.1021\/jm401893j","article-title":"Synthesis, structure-activity relationships, and biological studies of chromenochalcones as potential antileishmanial agents","volume":"57","author":"Shivahare","year":"2014","journal-title":"J.\u00a0Med. Chem."},{"key":"10.1016\/j.ejmech.2015.08.013_bib23","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1016\/0001-706X(93)90083-N","article-title":"A\u00a0comparison of three methods of estimating EC50 in studies of drug resistance of malaria parasites,","volume":"55","author":"Huber","year":"1993","journal-title":"Acta Trop."}],"container-title":["European Journal of Medicinal Chemistry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0223523415301975?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0223523415301975?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T13:43:18Z","timestamp":1759326198000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0223523415301975"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,9]]},"references-count":23,"alternative-id":["S0223523415301975"],"URL":"https:\/\/doi.org\/10.1016\/j.ejmech.2015.08.013","relation":{},"ISSN":["0223-5234"],"issn-type":[{"value":"0223-5234","type":"print"}],"subject":[],"published":{"date-parts":[[2015,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Aminothiazoles: Hit to lead development to identify antileishmanial agents","name":"articletitle","label":"Article Title"},{"value":"European Journal of Medicinal Chemistry","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejmech.2015.08.013","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2015 Elsevier Masson SAS. All rights reserved.","name":"copyright","label":"Copyright"}]}}